Using proprietary technologies to develop medicines and therapies that can repair tissues in the aged human body.
AgeX Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics targeting human aging. AgeX is building upon the foundation of their proprietary technologies such as PureStem® and induced Tissue Regeneration (iTR™) to develop innovative medicines designed to address some of the largest unsolved problems in aging.
Through PureStem®, AgeX has the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is AgeX’s revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
AgeX is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
AgeX was founded in 2017 and joined Juvenescence in 2018.